AEON Biopharma, Inc. (AEON) stock
AEONNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.15−0.01 (-3.59%)
Close on Nov 13, 2026Market cap $7.63MP/E –Yield –
AEON Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
AEON Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $7.18M, up 21.7% year over year. For fiscal 2025 it was $4.09M, down 71.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.09M | -71.1% |
| FY2024 | Dec 31, 2024 | $14.18M | -59.2% |
| FY2022 | Dec 31, 2022 | $34.75M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.94M | +176.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.03M | +146.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.61M | -47.0% |
| Q3 FY2025 | Sep 30, 2025 | $597.00K | -38.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.06M | -76.0% |
| Q1 FY2025 | Mar 31, 2025 | $825.00K | -85.6% |
| Q4 FY2024 | Dec 31, 2024 | $3.04M | -66.3% |
| Q3 FY2024 | Sep 30, 2024 | $972.00K | -89.4% |
| Q2 FY2024 | Jun 30, 2024 | $4.44M | -53.4% |
| Q1 FY2024 | Mar 31, 2024 | $5.73M | -23.3% |
| Q2 FY2023 | Jun 30, 2023 | $9.03M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.21M | – |
| Q4 FY2022 | Dec 31, 2022 | $9.53M | – |
| Q3 FY2022 | Sep 30, 2022 | $7.48M | – |
See a number that looks wrong?